INFU services are provided under a two-platform model. The first platform is Patient Services, providing last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair.
InfuSystem reported Q1 2026 net revenues of $33.7 million representing a 3% reduction from the prior year, net income of $1.0 million, and adjusted EBITDA margin expansion of 1% to 19%. In May 2026, the company announced a $20 million stock repurchase program authorized through June 30, 2028. The company operates in a stable healthcare segment with recurring revenue potential, though recent revenue contraction requires strategic focus.
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.
Open report →